Intellia Therapeutics, Inc.
Common Stock · USD · NASDAQ
Price
$13.675
Cap
—
Earnings
—
30d Trend
+2.6%
82% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 49×Macro 0.99 (−1%)=49
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
6-9 month momentum thesis — strong trend with confirmation
BRAIN47'S ASSESSMENT
I rate Intellia Therapeutics, Inc. at 49/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 80/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
+9.9%
3 MONTHS
-0.7%
12 MONTHS
+83.6%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
6-9 month momentum thesis — strong trend with confirmation. Momentum (80) and Technical (50) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 82%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.